Cost-effective therapy in patients with idiopathic hirsutism

References

• Uno H. Biology of hair growth. Semin. Repmd. Endocrinol 4,131–141 (1986).
   Google Scholar
• Ebling FJ. Hair. j Invest. Dermatol 67, 98–105 (1976).
   PubMedGoogle Scholar
• Schoemaker J. Hirsutism. In: Endocrinology and Metabolism. Pinchera A, Bertagna X, Fisher J (Eds). McGraw-Hill, London, UK, 569–572 (2001).
   Google Scholar
• Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 21, 347–362 (2000).
   PubMed Web of Science ®Google Scholar
• ••Interesting review on the pathogenesis andtreatment of idiopathic hirsutism.
   Google Scholar
• Jankovic SM, Jankovic SV. The control of hair growth. Dermatol Online' 4,2–6 (1998).
   PubMedGoogle Scholar
• Ahsan MK, Urano Y, Kato S, Osura H, Arase S. Immunohistochemical localization of thyroid hormone nuclear receptors in human hair follicles and in vitro effects of L-triiodothyroxine on cultured cells of hair follicles and skin. j Med. Invest. 44, 179–184 (1998).
   Google Scholar
• Blok GI de Boer H, Gooren LJ, van der Veen EA. Growth hormone substitution in adult growth-hormone deficient men augments androgen effects on the skin. Clin. Endocrinol 47,29-36 (1997).
   Google Scholar
• Goldfien A. Ovaries. In: Basic & Clinical Endocrinology Greenspan FS, Gardner DG (Eds). Lange Medical Books/McGraw-Hill, NY, USA, 453–508 (2001).
   Google Scholar
• Ebling FJG. Hair follicles and associated glands as androgen targets. Clin. Endocrinol Metab. 15,319–339 (1986).
   PubMedGoogle Scholar
• Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ, Lobo P Effects of sex steroids on skin 5a-reductase activity in vitro. Obstet. Cynecol 78,103–107 (1991).
   Google Scholar
• Hamada K, Thornton MJ, Laing I, Messenger AG, Randall VA. The metabolism of testosterone by dermal papilla cells cultured from human pubic and axillary hair follicles concurs with hair growth in 5a-reductase deficiency. j Invest. Dermatol 106,1017–1022 (1996).
   Google Scholar
• Yong CY, Murtha PE, Andrews PE, Lindzey JK, Tindall DJ. Antagonism of androgen action in prostate tumor cells by retinoic acid. Pmstate 25,39–45 (1994).
   Google Scholar
• Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride and spironolactone to treat idiopathic hirsutism. Fetid Steril 79,942–946 (2003).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that spironolactone inconjunction with an oral contraceptive is superior to other drugs as long-term follow-up to treat idiopathic hirsutism.
   Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. Clin. Endocrinol Metab. 21,1440–1447 (1961).
   Google Scholar
• •Reports the classical criteria of clinical assessment of body hair growth in women.
   Google Scholar
• Redmond GP. Clinical evaluation of the women with an androgenic disorder. In: Androgenic Disorders. Redmond GP (Ed.). Raven Press, NY, USA, 1–20 (1995).
   Google Scholar
• Azziz R, Waggoner WT, Ochoa T, Knochenhauser ES, Boots LR. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fetid Steril 70, 274–278 (1998).
   PubMed Web of Science ®Google Scholar
• Knochenhauser ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of polycystic ovarian syndrome in unselected black and white women of the Southeastern United States: a prospective study. j Clin. Endocrinol Metab. 83,3078-3082 (1998).
   Google Scholar
• Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am. j Obstet. Cynecol 167, 1807–1812 (1992).
   Google Scholar
• Carmina E. Prevalence of idiopathic hirsutism. Eur. Endocrinol 139,421–423 (1998).
   PubMed Web of Science ®Google Scholar
• McKenna TJ. Hirsutism and polycystic ovary syndrome. In: Clinical Endocrinology Grossman A (Ed). Blackwell Scientific Publication, London, UK, 740–760 (1998).
   Google Scholar
• Kokaly W McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen—progestogen combination. Gun. Endocrinol 52, 379–382 (2000).
   Google Scholar
• Dodin S, Faure N, Cerdin I et al. A Clinical efficacy and safety of low dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin. Endocrinol 43, 575–582 (1995).
   PubMedGoogle Scholar
• Taner C, Inal M, Basogul O et al. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet. Invest .54, 105–108 (2002).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that flutamide plus an oral contraceptive regimen is not superior to flutamide alone in the management of hirsutism.
   Google Scholar
• Peereboom-Wynia JDR, Boekhorst JC. Effect of cyproterone acetate orally in hair density and diameter and endocrine factors in women with idiopathic hirsutism. Dermatologica 160,7–16 (1980).
   Google Scholar
• Barth JH, Cherry CA, Wojnarowska F, Dawber RR Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Gun. Endocrinol 35,5–10 (1991).
   Web of Science ®Google Scholar
• Kelestimur F, Sahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil 69,66–69 (1998).
   PubMed Web of Science ®Google Scholar
• Venturoli S, Marescalchi O, Colombo FM et al A prospective randomized trial comparing low dose of flutamide, finasteride, ketoconazole and cyproterone acetate—estrogen regimens in the treatment of hirsutism. j Gun. Endocrinol Metab. 84, 1304–1310 (1999).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that the clinical utility of a contraceptive pills combined with cyproterone acetate and spironolactone in the treatment of hirsutism.
   Google Scholar
• Sahin Y, Bayram F, Kalestimur F, Muderris I. Comparison of cyproterone acetate plus etinyl estradiol and finasteride in the treatment of hirsutism. j Endocrinol Invest. 21,348–352 (1998).
   PubMed Web of Science ®Google Scholar
• Pawls F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 71,122–128 (1999).
   PubMedGoogle Scholar
• Raudrant D, Rabe T Progestogens with antiandrogenic properties. Drugs 63, 463–492 (2003).
   PubMed Web of Science ®Google Scholar
• Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358,1427–1429 (2001).
   Google Scholar
• •Established the risk of venous thromboembolism with cyproterone acetate is superior to risk of levonorgestrel contraceptives.
   Google Scholar
• Moghetti P, Tosi F, Tosti A et al Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: a randomized, double-blind, placebo-controlled trial. j Gun. Endocrinol Metab. 85,89–94 (2000).
   PubMed Web of Science ®Google Scholar
• Erenus M, Yikelten D, Garbilz O, Durmusoglu F, Pekin S. Comparison of spironolactone—oral contraceptive versus cyproterone acetate—estrogen regimens in the treatment of hirsutism. Fertil Steal 66, 216–219 (1996).
   Google Scholar
• Erenus M, Yikelten D, Durmusoglu F, Garbilz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fetid Stern. 68, 1000–1003 (1997).
   PubMed Web of Science ®Google Scholar
• Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. .1. Gun. Endocrinol Metab. 80, 233–238 (1995).
   Google Scholar
• Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute women. Gun. EndocrinoL 52,587–594 (2000).
   Google Scholar
• Wilson J. Androgens. In: Goodman and Gilman s The pharmacological Basis of Therapeutics. Gilman AG, Rall TW, Nies AS, Taylor P (Eds). McGraw-Hill, NY, USA, 1441–1457 (1996).
   Google Scholar
• Fruzzetti F, De Lorenzo D, Ricci C, Fioretti P. Clinical and endocrine effects of flutamide in hyperandrogenic women. FertiL SteriL 60,806–813 (1993).
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C et al Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes and androgen receptor behavior. Fertil Sten'''. 64,511–517 (1995).
   PubMed Web of Science ®Google Scholar
• Madderis II, Bayram F, Sahin Y, Kelestimur F, Tutus A, Ayata D. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil Steil'. 66, 220–222 (1996).
   PubMedGoogle Scholar
• Falsetti L, Gambera A. Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. Fetid Stern. 72, 41–46 (1999).
   PubMed Web of Science ®Google Scholar
• Dankoff JS. Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer. j Uml. 148, 1914–1925 (1991).
   Google Scholar
• Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. j Ural 155,209–212 (1996).
   PubMedGoogle Scholar
• Kassim NM, McDonald SW Reid O, Bennett NK, Gilmore DP, Payne AP The effects of pre- and postnatal exposure to the nonsteroid antiandrogen flutamide on testis descent and morphology in the Albino Swiss rat.J. Anat. 190,577–588 (1997).
   PubMed Web of Science ®Google Scholar
• Madderis II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/day) and finasteride (5 mg/day) in the treatment of hirsutism. Fetid Stern. 73,984-987 (2000).
   Google Scholar
• Rittmaster RS. Finasteride. N Engl. I Med. 330,120–125 (1994).
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Magmani CM et al Clinical and hormonal effects of the 5-CL reductase inhibitor finasteride in idiopathic hirsutism. j Gum. Endocrinol Metab. 79, 1115–1121 (1994).
   Google Scholar
• Ciotta L, Cianci A, Calogero A et al Clinical and endocrine effects of finasteride, a 5-CL reductase inhibitor in women with idiopathic hirsutism. Fetid Sten'''. 64,299–306 (1995).
   PubMed Web of Science ®Google Scholar
• Tolino A, Petrone A, Sarnacchiaro F et al Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Stern. 66,61–65 (1996).
   PubMed Web of Science ®Google Scholar
• Castello R, Tosi F, Perrone F, Negri C, Mugge° M, Moghetti P Outcome of long-term treatment with the 5-CL reductase inhibitor finasteride in idiopathic hirsutism. Clinical and hormonal effects during a 1 year course of therapy and 1 year follow-up. Fetid Steil" 66,734–740 (1996).
   Google Scholar
• Faloia E, Filipponi S, Mancini V, Di Marco S, Mantero F. Effects of finasteride in idopathic hirsutism. j Endocrinol Invest. 21,694–698 (1998).
   PubMedGoogle Scholar
• Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur. j Endoainol 141,361–367 (1999).
   Google Scholar
• •Demonstrates that flutamide is more effective than finasteride in reducing hair growth.
   Google Scholar
• Bayram F, Madderis II, Guven M, Kelestimur E Comparison of high-dose finasteride (5/mg/clay) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur Enclocrinol 147, 467–471 (2002).
   Google Scholar
• Sahin Y, Dither S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 75, 496–500 (2001).
   Google Scholar
• Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fetid Steil'. 61, 817–822 (1994).
   PubMed Web of Science ®Google Scholar
• Byahan G, Bahceci M, Demirkol T, Ertem M, Yalynkaia A, Erden AC. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Clin. Exp. Obstet. Cynecol 27, 203–206 (2000).
   PubMedGoogle Scholar
• Carmina E, Lobo RA. Gonadotropin- releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum. Reprod 12, 663–666 (1997).
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Martinez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone and hormone profile after 1-year use. Metabolism 46, 437–440 (1997).
   Google Scholar
• De Leo V, Fulghesu AM, la Marca A et al Hormonal and clinical effects of GnRII agonist alone, orin combination with a combined oral contraceptive or flutamide in women with severe hirsutism. Cynecol Endocrinol 14, 411–416 (2000).
   PubMed Web of Science ®Google Scholar
• Erenus M, Gurbuz O, Durmusoglu F, Demircay Z, Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil Stern. 61, 613–616 (1994).
   Google Scholar
• Unluhizarci KK, Everest H, Bayram F, Kelestimur F. Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Fetid. Steril 78, 1331–1333 (2002).
   PubMedGoogle Scholar
• Belisle S, Love EJ. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fetid. Steril 46, 1015–1020 (1986).
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Stern. 71, 445–451 (1999).
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18, 774–800 (1997).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann DA, Legro RS et al Troglitazone improves ovulation and hirsutism in the polycistystic ovary syndrome: a multicentric, double-blind, placebo-control trial. j Gun. Endocrinol Metab. 86, 1626–1632 (2001).
   PubMed Web of Science ®Google Scholar
• Azziz R. We should avoid the indiscriminate use of insulin sensitizers in women with polycistic ovary syndrome. Ferri]. Steril 80, 264–265 (2003).
   PubMedGoogle Scholar
• Ehrmann DA, Schneider DJ, Sobel BE et al Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J. Gun. Endocrinol Metab. 82, 2108–2116 (1997).
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Zhang G, Garmey JC. Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de nova androgen biosynthesis by thecal cell in vitro. J. Clin. Endocrinol Metab. 87, 1129–113 (2002).
   Google Scholar